Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: Is it cost-effective?

References

• The World Health Organisation. WHO, [cited 2004 Oct 6]; Available from: URL:, , http://www.who.int/en/.
   Google Scholar
• Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) in node positive breast cancer. The results of 20 years of follow up. N Engl J Med 1995; 332: 901–6
   PubMed Web of Science ®Google Scholar
• Levine M, Bramwell V, Pritchard K, Shepered L. CEF versus CMF in premenopausal women–recent update. Eur J Cancer 1998; 34(1)S35
   Google Scholar
• Norum J. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer. Is it cost effective?. Acta Oncol 2000; 39: 33–9
   PubMed Web of Science ®Google Scholar
• Statistics Norway. Statistisk sentralbyrå. [cited 2004 Aug 1]; Available from: URL:, , http://www.ssb.no.
   Google Scholar
• Irvin RJ, Kuhn JG. Financial considerations in the use of adjuvant chemotherapy. Adjuvant therapy of breast cancer, IC Henderson. Kluweer Academic Publishers. 1992; 207–22
   Google Scholar
• National Insurance Administration. Rikstrygdeverket. [cited 2004 Aug 15]; Available from: URL:, , http://www.trygdeetaten.no.
   Google Scholar
• Kornblith A, Hernon J, Weiss RB, et al. Long-term Adjustment of Survivors of Early-Stage Breast Carcinoma. 20 Years after Adjuvant Chemotherapy. Am Cancer Soc 2003; 98: 679–89
   Google Scholar
• Wefel J, Lenzi R, Theriault R, et al. The Cognitive Sequelae of Standard-Dose Adjuvant Chemotherapy in Women with Breast Carcinom. Results of a prospective randomized longitudinal trial. Cancer 2004; 11: 2292–9
   Google Scholar
• Norwegian Breast Cancer Group. NBCG. Norsk Bryst Cancer Gruppe. [Cited 2004 Aug 1]; Available from: URL:, , http://www.nbcg.net.
   Google Scholar
• Liljas B. How to calculate indirect costs in economic evaluations. Pharmacol Econ 1998; 13: 1–7
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 2002; (1)CD000487.
   Google Scholar
• Fumoleau P, Kerbrat P, Romestaing P, et al. Randomized trial comparing six versus three cycles of epirubicin based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 2003; 21: 298–305
   PubMed Web of Science ®Google Scholar
• Paradiso, A, Schittulli, F, Cellmare, G, et al. Randomized clinical trial of adjuvant fluorouracil, epirubicin, cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer.J Clin Oncol 2001;19:3929–37.
   PubMedGoogle Scholar
• French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 602–11
   PubMed Web of Science ®Google Scholar
• Trudeau ME. Optimizing adjuvant breast cancer chemotherapy: Rationale for the MA. 21 study. Oncology 2001; 15: 7–13
   PubMedGoogle Scholar
• Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrxate and fluorouracil in node-positive breast cancer. J Clin Oncol 2001; 19: 3103–10
   PubMed Web of Science ®Google Scholar
• Bergh J, Jønsson PE, Glimelius B, et al. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001; 40: 253–81
   PubMed Web of Science ®Google Scholar
• Brandberg Y, Michelson H, Nilsson B, et al. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow supported high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin or tailored therapy with fluorouacil, epirubicin and cyclophosphamide. J Clin Oncol 2003; 21: 3659–64
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Costantini M, Morasso G, et al. Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients. Eur J Cancer 2000; 38: 359–66
   Google Scholar
• Murray CJL, Lopez AD. The global burden of disease. World Health Organisation, Geneva 1996
   Google Scholar
• Cole BF, Gelber RD, Gelber S, et al. Polychemotherapy for early breast cancer: An overview of the randomised clinical trials with quality-adjusted survival. Lancet 2001; 358: 277–86
   PubMed Web of Science ®Google Scholar
• Jansen SJ, Kievit J, Nooij MA, et al. Patients‘preferences for adjuvant chemotherapy in early-stage breast cancer: Is treatment worthwhile?. Br J Cancer 2001; 84: 1577–85
   PubMedGoogle Scholar
• Glimelius B, Bergh J, Brandt L, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types-summary and conclusions. Acta Oncol 2001; 40: 135–54
   PubMed Web of Science ®Google Scholar
• Clifford A, Hudis. Current status and future directions in breast cancer therapy. Clin Breast Cancer 2003; 4: 70–5
   Google Scholar
• Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, fluorourrracil chemotherapy compared with cyclophosphamide, methotrxate and fluorouracil in premenopausal women with node-positive breastcancer. J Clin Oncol 1998; 16: 2651–8
   PubMed Web of Science ®Google Scholar
• Abrams J S. Adjuvant therapy for Breast Cancer-Results from the USA Consensus Conference. Breast Cancer 2001; 8: 298–304
   PubMedGoogle Scholar
• Broet P, Scholl S, Rochefordiere A, et al. Short and long term effects on survival in breastcancer patients treated by primary chemotherapy: An updated analysis of a randomised trial. Br Cancer Res Treat 1999; 58: 151–6
   PubMed Web of Science ®Google Scholar